Форсига

Quick links to important sections

Форсига

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Форсига

What is Formiga (Dapagliflozin)?

Property Description
Active ingredient Dapagliflozin
Form Oral, film-coated tablet
Pharmacological class SGLT2 inhibitor (Sodium-Glucose Cotransporter 2 inhibitor)
Origin Synthetic chemical drug
General purpose To aid the body in balancing sugar and fluid levels, supporting heart and kidney function.

What Type of Medicine is Formiga?

Formiga is a prescription medication available as a single-ingredient, film-coated tablet containing the active substance Dapagliflozin. It belongs to a modern pharmacological group known as SGLT2 inhibitors (Sodium-Glucose Cotransporter 2 inhibitors), a classification used globally.

This classification is significant because it defines a targeted approach that is fundamentally different from many older medicines, as the SGLT2 mechanism works independently of the body’s usual insulin pathways.

What Is the General Purpose of This Medicine?

The general purpose of Formiga is to help the body achieve better physiological balance by managing excess substances. It is a synthetic chemical drug that acts primarily on the kidneys to block the re-absorption of sugar, promoting its removal from the body through the urine.

This action of encouraging urinary excretion of sugar also causes the body to lose extra water and salt, which helps reduce overall fluid volume. This dual effect of lowering excess sugar and reducing metabolic burden offers supportive benefits for both the cardiovascular system and the kidneys.

What side effects are possible with Форсига?

Possible side effects and safety information

The official safety profile for Dapagliflozin (Formiga/Forxiga) details adverse reactions organized by frequency and the body system affected, strictly as documented by government health authorities such as the EMA and FDA.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence in clinical trials:

  • Very Common: Hypoglycaemia (low blood sugar), which is typically observed when the medicine is used in combination with insulin or an insulin secretagogue.
  • Common: Genital infections (such as vulvovaginitis and balanitis); urinary tract infections (UTIs); polyuria (increased frequency of urination); and nasopharyngitis (common cold).
  • Uncommon: Volume depletion, which may present as hypotension or dehydration; thirst; nocturia (waking at night to urinate); dry mouth; and constipation.

Serious Adverse Reactions and Safety Constraints

The regulatory label documents rare but serious adverse reactions that require clinical attention. These include Diabetic Ketoacidosis (DKA) and a serious perineal infection known as Fournier's Gangrene. Severe hypoglycaemia is a documented risk when the medicine is combined with insulin or sulfonylurea.

Safety notes specify that volume-related effects, such as hypotension, may be observed more frequently at the start of therapy and may be increased in older adults or those with renal impairment. The medication is explicitly contraindicated in the treatment of Type 1 Diabetes Mellitus due to the risk of DKA, a formal restriction in the official prescribing information.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for dapagliflozin overdose is based on clinical data showing a low risk of acute toxicity. In studies, single oral doses of dapagliflozin up to 500 mg (fifty times the maximum recommended dose) were administered to healthy subjects without acute, dose-limiting clinical effects. The only manifestations observed at these super-therapeutic doses were exaggerated pharmacological effects, specifically an increase in urinary glucose excretion and a subsequent increase in urinary volume.


Official Emergency Management Mandates

Management Aspect Regulatory Statement
Antidote No specific antidote is known.
Supportive Care Management must be symptomatic and supportive, as dictated by the patient’s clinical status.
Dialysis Efficacy The removal of dapagliflozin by hemodialysis has not been studied.

Required Immediate Action

Due to the need for clinical stabilization and monitoring, patients must seek immediate medical attention and contact a regional poison control centre for formal management of a suspected overdose. The supportive measures employed focus on managing volume loss and stabilizing the patient's general physiological status in a monitored setting. All official guidance strictly mandates urgent medical consultation for suspected overdose.

Therapeutic Uses of Форсига

What Форсига Treats: Main Uses and Benefits

This medicine is used across three major chronic health domains. It is applied in therapeutic areas where additional symptomatic support is needed, including Type 2 Diabetes Mellitus, Chronic Heart Failure, and Chronic Kidney Disease. The use of the medicine is focused on managing symptom clusters that may become intense or disruptive.

Comprehensive Support for Type 2 Diabetes Mellitus

This medication is commonly used to help with symptoms related to systemic imbalance by addressing persistently elevated blood sugar (hyperglycemia) in adults and pediatric patients aged 10 and older with Type 2 Diabetes. It is applied when blood sugar remains inadequately controlled. This supportive use is intended to assist with maintaining functional stability during periods of heightened symptoms associated with high blood sugar.

Cardio-Renal Symptom Management

Formiga is applied in conditions presenting with symptoms of heightened physiological stress, characteristic of symptomatic heart failure (both with reduced and preserved ejection fraction). The use of this medication assists with maintaining functional stability and may be part of symptomatic management in situations where patients experience heightened systemic burden. It is also commonly used to help with Chronic Kidney Disease (CKD). This use contributes to easing the overall symptom load and supports general well-being in the context of chronic kidney disease.


Quick Fact: Relief for Fluid Overload Symptoms Formiga is commonly used to help with symptoms associated with systemic fluid retention, such as breathlessness and edema (swelling), which are noticeable physiological manifestations of symptomatic heart failure.

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Official Eligibility Profile

Форсига (Dapagliflozin) eligibility is determined by specific population groups and pre-existing medical conditions, as defined by authoritative regulatory agencies.

Category Eligibility Status (Official Labeling)
Absolute Contraindications Contraindicated in patients with a history of a serious hypersensitivity reaction to the product. Also contraindicated in patients with End-Stage Renal Disease (ESRD) or those undergoing dialysis.
Age-Group Rules Approved for adults for all indications. For Type 2 Diabetes, approved for pediatric patients aged 10 years and older. Use is not established in children younger than 10 years.
Renal Function Thresholds Use for blood sugar control in Type 2 Diabetes is not recommended when the estimated Glomerular Filtration Rate ( eGFR) is below 45 mL/min/1.73 m^2. Initiation is not recommended when eGFR is below 25 mL/min/1.73 m^2.
Specific Exclusions Not recommended for the treatment of Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
Pregnancy/Lactation Not recommended during the second and third trimesters of pregnancy or for individuals who are breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Форсига (dapagliflozin) has documented interactions primarily based on pharmacodynamic effects and the requirement for patient monitoring and procedural adjustments.

Clinically Significant Pharmacodynamic Interactions

Co-administration with certain medicinal products requires careful monitoring due to additive effects:

  • Diuretics (Thiazide and Loop): Concomitant use increases the risk of volume depletion and hypotension because the effect on urinary volume is additive. Patients should be monitored for signs and symptoms of dehydration.
  • Insulin and Insulin Secretagogues (e.g., Sulfonylureas): The risk of hypoglycemia is increased when dapagliflozin is used with these medicines. A dose reduction of the co-administered insulin or secretagogue may be necessary.

Pharmacokinetic Interaction Profile

Dapagliflozin is primarily metabolized via UGT1A9 (Uridine 5′-diphospho-glucuronosyltransferase 1A9) to its major, inactive metabolite. Studies indicate dapagliflozin is not expected to cause clinically relevant inhibition or induction of drug metabolism by Cytochrome P450 (CYP) enzymes. Consequently, no clinically significant pharmacokinetic interactions were observed with tested medicines such as metformin, simvastatin, digoxin, warfarin, or hydrochlorothiazide.

Interaction-Related Constraints

The medicine should be temporarily withheld for at least 3 days prior to major surgery or procedures associated with prolonged fasting. Use in elderly patients, who are often on antihypertensive medicines, requires consideration of the risk of volume depletion.

Mechanism of Action

The drug's mechanism involves targeted biological action on key regulatory systems within the kidneys, initiating several downstream physiological changes.

Targeted Blockade of Glucose Reabsorption

This domain focuses on the molecular action of the drug as a selective inhibitor of the Sodium-Glucose Co-transporter 2 (SGLT2) protein located in the kidney tubules. Blocking this transport prevents the reabsorption of most filtered glucose and a portion of sodium back into the circulation, causing the excretion of glucose in the urine (glucosuria).

Dual Modulation of Fluid Balance and Renal Pressure

The resulting increase in solute excretion activates two related mechanisms: the increased sodium delivery triggers the tubuloglomerular feedback system, which causes a reduction in pressure within the kidney’s filtering units (glomeruli). The osmotic effect of the solutes causes water to follow them out of the body, leading to a modest reduction in total circulating fluid volume. This combined action influences renal hemodynamics and results in the full range of the drug's known physiological consequences.

Dosage and Administration Information

How Форсига (Dapagliflozin) is Used

The use of dapagliflozin follows standardized protocols and is intended for continuous, long-term chronic management. The medicine is administered through the oral route as a film-coated tablet.

Standard Administration Protocol

Parameter Administration Details
Form and Route Oral administration of a film-coated tablet.
Frequency Taken once daily.
Timing May be taken at any time of day, with or without food.
Adult Dose The standard dose for most approved adult indications is 10 mg once daily.

Use in Specific Populations

Dosing adjustments apply to certain patient groups. For pediatric patients (aged 10 and older) with Type 2 Diabetes Mellitus, the initial dose is 5 mg once daily, with the possibility of increasing to 10 mg based on tolerability and response. For adults with severe hepatic impairment, the initial dose is 5 mg. Furthermore, initiating treatment is generally not recommended for adult patients exhibiting an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m^2.

Handling Missed Doses

If a dose is forgotten, it is typically taken upon remembering. However, if the time is close to the next scheduled dose, the missed dose is skipped. A double dose is not taken to compensate for a missed dose.

Recent Clinical Evidence

Recent Clinical Evidence for Dapagliflozin

Dapagliflozin (Forxiga or Farxiga) belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Initial research focused on its use in type 2 diabetes (T2D) to improve blood glucose control, which is achieved by blocking SGLT2 in the kidney and promoting glucose excretion in the urine.


Cardiorenal Outcome Trials

Recent major clinical trials have expanded the understanding of dapagliflozin's effects beyond blood sugar management, focusing on outcomes related to the heart and kidneys. These studies evaluated the drug's use in different patient populations, including those with and without T2D.

  • Chronic Heart Failure (HF): In trials involving patients with heart failure (specifically with reduced ejection fraction), the addition of dapagliflozin to standard care was associated with a lower rate of cardiovascular death and hospitalization due to heart failure, regardless of the patient's diabetes status.

  • Chronic Kidney Disease (CKD): Dedicated renal outcomes trials have explored the drug's effect in patients with chronic kidney disease, both with and without T2D. Findings indicated an association with a slower rate of kidney function decline, a lower incidence of end-stage kidney disease, and reduced risk of cardiovascular death or hospitalization for heart failure.


Safety Profile Summary

Across the extensive clinical program, the most commonly reported side effects included genital mycotic infections and urinary tract infections, which are related to the drug's mechanism of action. Other reported events were volume depletion, which may lead to low blood pressure, and a minor, non-progressive initial decrease in estimated glomerular filtration rate (eGFR), which is linked to the drug's effects on kidney hemodynamics.

Frequently Asked Questions (FAQ)

Common questions about Форсига (FAQ)


Q: What is the main reason doctors prescribe Форсига?

A: According to official drug regulatory information, Форсига is approved for use in adults for Type 2 Diabetes Mellitus, Chronic Kidney Disease (CKD), and heart failure. Specifically, it is approved for certain heart failure conditions, including both reduced and preserved ejection fraction (HFrEF and HFpEF).


Q: Is Форсига used for weight loss, or is that just a side effect?

A: Форсига is not approved by regulators as a specific weight loss treatment. Its primary function is to help the body excrete glucose and calories in the urine. Because of this mechanism, weight loss is a common effect that was observed in clinical trials.


Q: How long does it take to see the effects of Форсига?

A: The effect of lowering blood glucose begins within a few hours of taking the first dose. However, for chronic conditions such as heart failure or chronic kidney disease, the full, long-term clinical benefits may take several weeks or months to become apparent.


Q: Do the benefits of Форсига stop if you stop taking the medicine?

A: Форсига is intended for continuous, long-term management of chronic conditions like diabetes, heart failure, and chronic kidney disease. The beneficial effects on blood sugar, heart, and kidney function are sustained only for the duration of treatment, according to the official product information.


Q: Are there any common supplements or vitamins that should not be taken with Форсига?

A: No specific vitamins or general supplements are listed in regulatory documents as having a major interaction. However, due to the drug's effect on fluid balance, it is important that patients discuss all supplements and vitamins with their prescribing healthcare provider, particularly those that may affect fluid balance.


Q: Is it normal to feel more thirsty when taking Форсига?

A: Increased thirst (polydipsia) is an uncommon but reported side effect in clinical trials. This is expected because the drug works by increasing the loss of fluid and glucose in the urine, which can lead to volume depletion or dehydration.


Q: Why do people who do not have diabetes also take Форсига?

A: The drug is approved for the treatment of certain types of chronic heart failure and chronic kidney disease, which are serious conditions that affect people regardless of their diabetes status. Therefore, the drug's use is not limited solely to patients with Type 2 Diabetes Mellitus.


Q: What are the most commonly reported side effects of Форсига?

A: Regulatory documents list the most common side effects as genital fungal infections (yeast infections), urinary tract infections, and increased urination. The risk of low blood sugar is also increased when this medicine is taken in combination with certain other diabetes medicines, such as insulin.


Q: Is it true that Форсига can help with heart problems?

A: Yes. The drug has specific regulatory approval to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with certain chronic heart failure conditions. This benefit was demonstrated in large-scale clinical trials.


Q: Does Форсига interact with common pain relievers like ibuprofen?

A: Common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are not listed as having a direct pharmacological interaction. However, regulatory warnings note that NSAIDs can sometimes affect kidney function, and this means that the concurrent use requires careful consideration by a healthcare provider.


Q: Is it safe to drive or operate machinery while taking Форсига?

A: Форсига generally has little to no impact on the ability to drive or use machines. However, if the drug is taken with other diabetes medicines that can cause low blood sugar (hypoglycemia), this combination could potentially cause dizziness and affect concentration.


Q: What kind of studies have been done on the long-term effects of Форсига?

A: The drug has been studied in extensive, large-scale, long-term cardiovascular outcome trials (CVOTs). These studies tracked the drug's effects on major health events, such as heart attack, stroke, heart-related death, and kidney disease progression, over several years.


Q: Are there any reported interactions between Форсига and alcohol?

A: Official information advises caution regarding alcohol use, especially for patients with diabetes, as alcohol can affect blood sugar levels. When taken with other specific diabetes medicines (like metformin), alcohol can also increase the risk of serious complications such as lactic acidosis.


Q: Can Форсига cause changes in cholesterol levels?

A: According to the observed adverse reactions from clinical trials, the drug has been shown to result in small changes in blood cholesterol. Specifically, small increases in both HDL-cholesterol (often called 'good' cholesterol) and LDL-cholesterol (often called 'bad' cholesterol) have been noted.


Q: How is the benefit of Форсига measured by a healthcare provider?

A: For Type 2 diabetes, the drug's benefit is measured primarily by assessing blood sugar control, such as A1C levels. For heart failure and chronic kidney disease, benefit is measured by monitoring specific disease markers, slowing the progression of the condition, and reducing the risk of hospitalization.


Q: If I have a history of bladder infections, can I still use Форсига?

A: Since the drug may increase the risk of urinary tract infections (UTIs) and genital infections, caution is advised. While a history of infection is not usually a formal prohibition, patients with recurrent infections are advised to seek guidance from their healthcare provider, as monitoring may be part of their care plan.


Q: What is the difference between a side effect and an allergic reaction to Форсига?

A: A side effect, such as increased urination or a yeast infection, is a known, non-allergic effect reported in clinical trials. An allergic reaction is a serious and rare immune response that may involve symptoms like rash, hives, or swelling of the face, and it requires immediate medical attention.


Q: Can Форсига affect the results of other medical tests?

A: Yes. Due to the mechanism of action, the drug causes increased glucose to be passed through the urine. As a result, regulatory warnings note that patients taking this medicine will test positive for glucose in certain urine-based laboratory tests.


Q: Why are people talking about Форсига for heart failure?

A: People are discussing it because the drug has specific regulatory approval for heart failure. Official information states it is indicated to reduce the risk of cardiovascular death and hospitalization in adults with certain heart failure conditions, regardless of whether the patient has diabetes.


Q: Can men and women expect different effects from taking Форсига?

A: Yes, according to adverse reaction data. The risk of genital fungal infections (yeast infections) is significantly higher in women than in men. However, the risk of urinary tract infections is increased for both sexes.


Q: Is it safe to continue taking Форсига during a minor illness like a cold?

A: When experiencing an acute illness or conditions that can lead to volume depletion, such as severe vomiting or diarrhea, there is an increased risk of dehydration and ketoacidosis. Any significant illness requires guidance from a healthcare provider regarding continued medication use.


Q: Can someone who is overweight but does not have diabetes use Форсига?

A: The drug is approved for the treatment of certain types of heart failure and chronic kidney disease, which are conditions that affect both diabetic and non-diabetic individuals. While weight loss is a noted effect, the drug is not approved solely for weight management.


Q: Is there research evidence showing Форсига's effect on major health events?

A: Yes. Regulatory approval is supported by clinical studies that demonstrated the drug significantly reduced the risk of major health events, including hospitalization for heart failure and the progression of chronic kidney disease in the trial populations.


Q: Why is it necessary to check for ketones while taking Форсига?

A: Regulatory warnings mention that the drug can increase the risk of diabetic ketoacidosis (DKA), a serious condition involving high ketone levels. This is a concern because DKA can sometimes occur with this drug even if blood sugar levels are only mildly elevated.


Q: Does Форсига interact with birth control pills?

A: Official interaction studies generally indicate no clinically significant interaction between Форсига and hormonal contraceptives (birth control pills). However, blood glucose levels should still be monitored, as some oral contraceptives can independently affect blood sugar control.


Q: What if I have an existing heart condition, is Форсига still appropriate?

A: For many patients, yes. The drug is specifically approved to reduce the risk of cardiovascular death and hospitalization in adults who have certain existing chronic heart failure conditions.


Q: Can taking Форсига cause yeast infections?

A: Yes. Genital fungal (yeast) infections are listed as a common side effect in the official product information for both men and women. This is because the drug works by increasing the amount of sugar passed out in the urine.


Q: Does Форсига need to be refrigerated or is it stored at room temperature?

A: The tablets should be stored at controlled room temperature, typically between 20 °C to 25 °C (68 °F to 77 °F).


Q: Does the effectiveness of Форсига decrease over time?

A: Clinical studies lasting up to two years have demonstrated that the drug's key effects, including increased urinary glucose excretion and its benefits on heart and kidney function, are generally sustained over the duration of treatment.


How should Форсига be stored and disposed of?

Storage and Disposal of FORXIGA (dapagliflozin)

FORXIGA tablets must be stored at controlled room temperature, maintaining a range from 20 C to 25 C (68 F to 77 F). The official labeling permits brief temperature excursions between 15 C and 30 C.

The medicine should be kept in its original container to maintain product quality and must be secured out of the sight and reach of children to prevent accidental ingestion.

Disposal

Disposal of any unused or expired tablets must be completed in accordance with local requirements. Patients are instructed to utilize authorized drug take-back programs or follow specific local and national guidelines for discarding medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Форсига found in:

A-Z Index: